Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + docetaxel + doxorubicin
- Development stage
- Phase 3
- Lead developer
- GOG Foundation
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Gemcitabine + docetaxel + doxorubicin is a triple-drug combination chemotherapy regimen investigated for the treatment of advanced, unresectable, or metastatic sarcomas, particularly uterine leiomyosarcoma, as well as breast cancer and non-small cell lung cancer. The regimen combines three distinct mechanisms of action: gemcitabine is a nucleoside analog that inhibits DNA synthesis; docetaxel is a taxane that stabilizes microtubules to arrest cell division; and doxorubicin is an anthracycline that intercalates DNA and inhibits topoisomerase II. This combination is typically used in sequential or modified schedules (such as gemcitabine and docetaxel followed by doxorubicin) to optimize synergistic antitumor effects while managing cumulative toxicities like myelosuppression and cardiotoxicity. It is primarily studied in clinical trials sponsored by cooperative groups like the GOG Foundation and SARC.
- Other names
- gemcitabine-docetaxel-doxorubicinGDD regimenGem-Tax-Dox
02
Targets
Top2cc (DNA / DNA-topoisomerase II cleavage complexes)DNA polymerase familyRNR (Ribonucleotide reductase)DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on gemcitabine + docetaxel + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + docetaxel + doxorubicin.